CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced today it has received the 2024 MedTech Breakthrough Award ...
PH is a progressive, life-threatening pulmonary vascular disease estimated to affect up to 1% of the global population. 1 It is often difficult to diagnose 2 due to non-specific early symptoms, such ...
Real-world evidence to be presented at the American College of Cardiology Scientific Session 2026 highlights impact of Viz HCM, developed as part of a multi-year agreement with Bristol Myers Squibb, ...
An artificial intelligence (AI)-based method for interpreting ECGs performed better than standard approaches in detecting ...
San Francisco-based AliveCor has received FDA clearance for two new algorithms for its smartphone-connected ECG: one that detects normality and one that detects interference. These follow up on ...
A new clinical study shows that PulseAI’s deep learning AI demonstrates superiority over the Apple Watch ECG in the detection of atrial fibrillation. Results have been accepted for presentation at the ...
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UCSF study finds that Artificial Intelligence-enhanced ...
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available “At Anumana, we are committed to developing ...